Geode Slowly Boosts STSA Stock Stake

According to a recent Form 13F filing submitted to the SEC, Geode Capital Management, Llc disclosed a noteworthy and bullish investment in STSA stock. Here’s what you need to know about Satsuma Pharmaceuticals, Inc., as well as Geode Capital Management and their long position in shares of STSA stock:

About Geode Capital Management, LLC

Boston, Massachusetts-based Geode Capital Management is a systematic asset manager providing core beta exposures across a range of equity and niche asset classes. Geode was founded in 2001 and set out to create structured and repeatable investment strategies with the objective of providing efficient exposures to institutional investors.

About Satsuma Pharmaceuticals, Inc. (STSA)

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. STSA’s lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can be self-administered with proprietary pre-filled, single-use, and nasal delivery device. Satsuma Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Geode Capital Management Buys Stock in STSA

According to the most recent 13F filed by Geode Capital Management the firm added 26,707 shares of STSA stock to it holdings in the recent quarter. That brings their total long position in Satsuma Pharmaceuticals, Inc. to 191,445 shares, representing approximately 0.5779% of the 33,126,000 STSA shares outstanding. Based on the most recent closing price of $4.05 per share of STSA, the entire Geode Capital Management position in Satsuma Pharmaceuticals, Inc. is worth roughly $775,352.25.

Summary

Be sure to check out more recent 13F filings here to stay up to date on the latest disclosures from institutional investment managers like Geode Capital Management, LLC. Also be sure to check out more recent 13F filing analysis news here.